BRAF mutation (any)

Any BRAF mutation (V600 and non-V600 classes) detected by sequencing; used as a predictive and, in some settings, prognostic marker.

CI-BIO-00000019BRAF graph →NCIt C40430 Tumor-agnostic · 4 approval rows

Also calledBRAF-mutant · BRAF-mutated · non-V600 BRAF · class II/III BRAF

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (32)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Melanoma	75	72	2	1	3 / 40 / 14 / 18 / 0
Malignant Colorectal Neoplasm	67	54	13	—	1 / 43 / 10 / 12 / 1
Cutaneous Melanoma	22	22	—	—

Derived

Drugs with predictive evidence (43)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	92	72	20	A	55 / 22	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +16
TrametinibSmall Molecule	53	51	2	A	50 / 2	Childhood Low Grade Glioma, Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma +13
DabrafenibSmall Molecule	40	33	7	A	34 / 11	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Ganglioglioma +9
CetuximabMonoclonal Antibody	24	11	13	A	9 / 10	Malignant Colorectal Neoplasm, Solid Neoplasm
PanitumumabMonoclonal Antibody	14	8	6	B	5 / 4	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	12	5	7	B	5 / 6	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	10	9	1	C	9 / 1	Childhood Pilocytic Astrocytoma, Cutaneous Melanoma, Malignant Colorectal Neoplasm, Melanoma +1
CobimetinibSmall Molecule	7	7	—	A	8 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	6	6	—	A	6 / 0	Malignant Colorectal Neoplasm, Melanoma
Mitogen-Activated Protein Kinase Kinase Inhibitor	6	6	—	B	5 / 0	Cutaneous Melanoma, Melanoma
BevacizumabMonoclonal Antibody	5	3	2	B	3 / 2	Malignant Colorectal Neoplasm, Spindle Cell Sarcoma
BRAF Inhibitor	5	5	—	B	4 / 0	Melanoma
SelumetinibSmall Molecule	5	4	1	B	2 / 2	Childhood Pilocytic Astrocytoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
OxaliplatinSmall Molecule	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm, Melanoma
TovorafenibSmall Molecule	2	2	—	A	4 / 0	Childhood Low Grade Glioma
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
TemsirolimusSmall Molecule	2	2	—	C	2 / 0	Spindle Cell Sarcoma
U0126	2	—	2	D	0 / 2	Cutaneous Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
Regorafenib AnhydrousSmall Molecule	2	1	1	C	0 / 1	Gastrointestinal Stromal Tumor
MEK Inhibitor RO4987655	2	—	2	B	—	Melanoma
AlpelisibSmall Molecule	1	1	—	B	1 / 0	Malignant Colorectal Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	A	1 / 0	Melanoma
BelvarafenibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Chemotherapy	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
Dabrafenib/Trametinib Regimen	1	1	—	C	1 / 0	Histiocytic Sarcoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
EverolimusSmall Molecule	1	1	—	D	1 / 0	Childhood Low Grade Glioma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
MEK Inhibitor REC-4881	1	1	—	C	1 / 0	Cutaneous Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
Pan-RAF Inhibitor LY3009120Small Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
RefametinibSmall Molecule	1	—	1	C	0 / 1	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (214)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 201–214 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E8
Vemurafenib	Ovarian Serous AdenocarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID3787 A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard ch… (full text at CIViC) PMID 26490654 · Combe et al., 2015 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12161 In this trial, patients with advanced rare tumours harbouring BRAF V600E mutations were treated with a combination of dabrafenib and trametinib. The study included eight distinct cohorts: anaplastic t… (full text at CIViC) PMID 37059834 · Subbiah et al., 2023 · Open in CIViC	civic
〃	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	4	accepted	EID6975 Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11/16 patients with anap… (full text at CIViC) PMID 29072975 · Subbiah et al., 2018 · Open in CIViC	civic
Vemurafenib	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID6045 In a phase 2 “basket” study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete res… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
Pertuzumab + VemurafenibCombination	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID5961 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
Vemurafenib	Thyroid Gland Papillary CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID1591 Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort… (full text at CIViC) PMID 27460442 · Brose et al., 2016 · Open in CIViC	civic
〃	Thyroid Gland Papillary CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	4	accepted	EID9018 Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positiv… (full text at CIViC) PMID 27460442 · Brose et al., 2016 · Open in CIViC	civic
〃	Thyroid Gland Papillary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	4	accepted	EID1414 A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the … (full text at CIViC) PMID 24987354 · Ali et al., 2014 · Open in CIViC	civic
BRAF L525R1
Cetuximab	Solid NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	3	accepted	EID7560 When transferred into EGFR expressing HEK293 cells, BRAF L525R induced increased ERK phosphorylation to a level similar to that induced by BRAF V600E. ERK phosphorylation enhanced by BRAF L525R was no… (full text at CIViC) PMID 28972961 · Shinozaki et al., 2017 · Open in CIViC	civic
BRAF Non-V6001
Trametinib	Solid NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID7855 In a phase II basket trial (NCI-MATCH), patients with solid tumors or hematologic malignancies harboring BRAF non-V600 mutations were treated with trametinib. Among 50 patients assigned, 32 were eligi… (full text at CIViC) PMID 31924734 · Johnson et al., 2020 · Open in CIViC	civic
BRAF G466V1
Vemurafenib	Solid NeoplasmCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID7554 RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R). PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
BRAF Fusion2
Bevacizumab + Sorafenib + TemsirolimusCombination	Spindle Cell Sarcoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID1664 A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinas… (full text at CIViC) PMID 24422672 · Subbiah et al., 2014 · Open in CIViC	civic
〃	Spindle Cell Sarcoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID7312 A patients with malignant spindle cell tumor treated as as soft tissue sarcoma harboring KIAA1549-BRAF fusion were treated with sorafenib in combination with bevacizumab and temsirolimus. Tumor of th… (full text at CIViC) PMID 26314551 · Ross et al., 2016 · Open in CIViC	civic
BRAF Fusion1
Trametinib	Transitional Cell Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7763 In a case report, a patient with metastatic urothelial carcinoma harboring an NRF1-BRAF fusion was treated with trametinib. After two and a half months of treatment, MRI revealed 48.4% decrease in siz… (full text at CIViC) PMID 31010895 · Isaacson et al., 2019 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (458)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpdRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Irinotecan	CA Health Canada	—	Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION, USP (DIN 02452421) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 22, 2024	health-canada-dpd
Irinotecan	CA Health Canada	—	Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02528789) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 28, 2024	health-canada-dpd
Irinotecan	CA Health Canada	—	Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02501279) under ATC L01CE02 IRINOTECAN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (629)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 333 recruiting · 118 active phase 3 · 2,987 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 101–150 of 629 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03715933	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	recruiting	Phase 1	411	Inhibrx Biosciences, IncINDUSTRY	6	Sep 8, 2026	clinicaltrials
NCT07228832	Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer(HARMONi-GI3)	recruiting	Phase 3	600	Summit TherapeuticsINDUSTRY	14	Sep 8, 2026	clinicaltrials
NCT02642042	Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer	active not recruiting	Phase 2	60	National Cancer Institute (NCI)NIH	1	Sep 4, 2026	clinicaltrials
NCT04005690	Targeted Pathway Inhibition in Patients With Pancreatic Cancer	recruiting	Early Phase 1	90	OHSU Knight Cancer InstituteOTHER	1	Sep 4, 2026	clinicaltrials
NCT04340141	Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer	active not recruiting	Phase 3	358	Alliance for Clinical Trials in OncologyOTHER	2	Sep 4, 2026	clinicaltrials
NCT04589845	Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	active not recruiting	Phase 2	920	Hoffmann-La RocheINDUSTRY	23	Sep 4, 2026	clinicaltrials
NCT06400472	A Study of Sofe-M in Participants With Selected Advanced Solid Tumors	recruiting	Phase 1	575	Eli Lilly and CompanyINDUSTRY	7	Sep 4, 2026	clinicaltrials
NCT03178552	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)(B-FAST)	active not recruiting	Phase 2 / Phase 3	1,000	Hoffmann-La RocheINDUSTRY	27	Sep 3, 2026	clinicaltrials
NCT04657991	A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma	active not recruiting	Phase 3	257	PfizerINDUSTRY	27	Sep 3, 2026	clinicaltrials
NCT05673148	Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial	recruiting	Phase 2	146	Alliance for Clinical Trials in OncologyOTHER	2	Sep 3, 2026	clinicaltrials
NCT06252649	Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301)	recruiting	Phase 3	450	AmgenINDUSTRY	35	Sep 3, 2026	clinicaltrials
NCT06271837	A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors	active not recruiting	Phase 2	127	AstraZenecaINDUSTRY	1	Sep 3, 2026	clinicaltrials
NCT06824467	A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)	recruiting	Phase 3	770	Merck Sharp & Dohme LLCINDUSTRY	29	Sep 3, 2026	clinicaltrials
NCT07110246	Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas(PNOC037)	recruiting	Phase 2	96	University of California, San FranciscoOTHER	1	Sep 3, 2026	clinicaltrials
NCT07441707	A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours	active not recruiting	Phase 1	6	IpsenINDUSTRY	1	Sep 3, 2026	clinicaltrials
NCT07801027	A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)	not yet recruiting	Phase 4	150	Merck Sharp & Dohme LLCINDUSTRY	0	Sep 3, 2026	clinicaltrials
NCT07801352	CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer	active not recruiting	Phase 2	15	Shanghai Changzheng HospitalOTHER	1	Sep 3, 2026	clinicaltrials
NCT05862285	A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study(UmbrellaMAX)	recruiting	Phase 3	100	Hoffmann-La RocheINDUSTRY	15	Sep 2, 2026	clinicaltrials
NCT06632327	Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer	active not recruiting	Phase 3	37	Alliance for Clinical Trials in OncologyOTHER	1	Sep 2, 2026	clinicaltrials
NCT07216105	FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors	recruiting	Phase 1	119	Fate TherapeuticsINDUSTRY	1	Sep 2, 2026	clinicaltrials
NCT07252739	KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)	recruiting	Phase 2	140	Merck Sharp & Dohme LLCINDUSTRY	13	Sep 2, 2026	clinicaltrials
NCT07283939	Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays	recruiting	N/A	420	Alliance for Clinical Trials in OncologyOTHER	3	Sep 2, 2026	clinicaltrials
NCT07293247	A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment	recruiting	Phase 2	164	Alliance for Clinical Trials in OncologyOTHER	1	Sep 2, 2026	clinicaltrials
NCT07363408	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	not yet recruiting	Phase 1	30	City of Hope Medical CenterOTHER	1	Sep 2, 2026	clinicaltrials
NCT03600701	Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer	active not recruiting	Phase 2	53	National Cancer Institute (NCI)NIH	1	Sep 1, 2026	clinicaltrials
NCT04557956	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	active not recruiting	Phase 1 / Phase 2	16	National Cancer Institute (NCI)NIH	1	Sep 1, 2026	clinicaltrials
NCT04570423	A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy	recruiting	Phase 2	40	Spectrum Pharmaceuticals, IncINDUSTRY	1	Sep 1, 2026	clinicaltrials
NCT05355701	A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.	active not recruiting	Phase 1	103	PfizerINDUSTRY	3	Sep 1, 2026	clinicaltrials
NCT05627635	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer	active not recruiting	Phase 1 / Phase 2	20	City of Hope Medical CenterOTHER	1	Sep 1, 2026	clinicaltrials
NCT05945823	Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors	active not recruiting	Phase 2	53	Taiho Oncology, Inc.INDUSTRY	4	Sep 1, 2026	clinicaltrials
NCT06576037	Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin	recruiting	Phase 1	128	M.D. Anderson Cancer CenterOTHER	1	Sep 1, 2026	clinicaltrials
NCT06730750	A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors	active not recruiting	Phase 1 / Phase 2	360	Bristol-Myers SquibbINDUSTRY	3	Sep 1, 2026	clinicaltrials
NCT07564141	Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer(RAINFOL™-07)	recruiting	Phase 3	688	GenmabINDUSTRY	1	Sep 1, 2026	clinicaltrials
NCT07322341	SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer	recruiting	Phase 2	32	University of WashingtonOTHER	1	Aug 31, 2026	clinicaltrials
NCT07793942	A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)	not yet recruiting	Phase 2	480	Merck Sharp & Dohme LLCINDUSTRY	0	Aug 31, 2026	clinicaltrials
NCT00588770	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	active not recruiting	Phase 3	403	National Cancer Institute (NCI)NIH	3	Aug 28, 2026	clinicaltrials
NCT02142803	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	active not recruiting	Phase 1	50	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	Phase 2	34	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT02224781	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	active not recruiting	Phase 3	267	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT04449874	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	active not recruiting	Phase 1	498	Genentech, Inc.INDUSTRY	17	Aug 28, 2026	clinicaltrials
NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	active not recruiting	Phase 4	163	Novartis PharmaceuticalsINDUSTRY	19	Aug 27, 2026	clinicaltrials
NCT05700084	Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors	active not recruiting	Phase 1 / Phase 2	84	Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY	1	Aug 27, 2026	clinicaltrials
NCT06783647	A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]	recruiting	Phase 2	250	Nanjing Leads Biolabs Co.,LtdINDUSTRY	1	Aug 27, 2026	clinicaltrials
NCT07474727	A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer	recruiting	Phase 2	180	Multitude Therapeutics Inc.INDUSTRY	1	Aug 27, 2026	clinicaltrials
NCT07790510	HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer	recruiting	Phase 1 / Phase 2	180	Haisco Pharmaceutical Group Co., Ltd.INDUSTRY	1	Aug 27, 2026	clinicaltrials
NCT04329494	PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer	recruiting	Phase 1	49	City of Hope Medical CenterOTHER	1	Aug 26, 2026	clinicaltrials
NCT06313970	First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients	active not recruiting	Phase 2	58	Fudan UniversityOTHER	1	Aug 26, 2026	clinicaltrials
NCT07786766	Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma	recruiting	Phase 2	154	Haitao Zhao, MDOTHER	1	Aug 26, 2026	clinicaltrials
NCT04847063	Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies	recruiting	Phase 1	60	National Cancer Institute (NCI)NIH	1	Aug 25, 2026	clinicaltrials
NCT06818812	A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	active not recruiting	Phase 1	30	Incyte CorporationINDUSTRY	1	Aug 25, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (32)

Drugs with predictive evidence (43)

Predictive evidence items (214)

Approvals mentioning the linked drugs (458)

Active trials (629)

Linked publications (142)